Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome

Marion, Chad R.; Izquierdo, Manuel; Hanes, Holly; Barrios, Christopher

doi:10.1007/s11882-020-00985-7

Cited by 8 publications

(6 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cascade of factors is accountable including physiology and environment [ 2 ]. The main symptoms of bronchial asthma are shortness of breath, sudden wheezing, cough, and chest discomfort [ 3 ]. The disease is more common in individuals with allergic constitutions and individuals with low resistance [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Fluticasone and Salmeterol Dry Powder in Treating Patients with Bronchial Asthma and Its Effect on Inflammatory Factors and Pulmonary Function

Zhang

Liu

Mao

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To evaluate the efficacy of fluticasone and salmeterol dry powder in treating patients with bronchial asthma and its effects on inflammatory factors and pulmonary function. Methods. One hundred patients with bronchial asthma, admitted to our hospital between April 2019 and June 2020, were enrolled and assigned into two groups using the random number table method. The observation group (n = 50) received budesonide powder, and the experimental group received fluticasone and salmeterol dry powder. The two groups were compared with regard to clinical efficacy, inflammatory factors, pulmonary function, and adverse reactions. Results. In the experimental group, the total effective rate of treatment was significantly higher than that in the observation group ( P < 0.05 ); after treatment, the levels of inflammatory factors in the experimental group were lower than those in the observation group ( P < 0.05 ); after treatment, lung function in the experimental group was significantly higher than that in the observation group ( P < 0.05 ); the incidence of adverse reactions in the experimental group was significantly lower than that in the observation group ( P < 0.05 ). Conclusion. Salmeterol and fluticasone powder has shown impressive clinical benefits in the treatment of bronchial asthma patients. It might be a viable approach to reduce inflammatory factors and improve pulmonary function. Moreover, its good clinical safety profile makes it a promising treatment that ought to be promoted and used widely.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Fluticasone and Salmeterol Dry Powder in Treating Patients with Bronchial Asthma and Its Effect on Inflammatory Factors and Pulmonary Function

Zhang

Liu

Mao

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“… 5 The ideal situation would be to individually verify if the patients inform changes in their daily living after BD inhalation and present positive BDR, which could mean a CF-asthma overlap syndrome. 27 …”

Section: Discussionmentioning

confidence: 99%

Bronchodilator response assessment through impulse oscillometry system and spirometry in children and adolescents with cystic fibrosis

Castilho,

Ribeiro,

Wamosy

et al. 2024

Rev. paul. pediatr.

View full text Add to dashboard Cite

Objective: To investigate the effect of bronchodilator on the respiratory mechanics and pulmonary function of children and adolescents with cystic fibrosis. Methods: Cross-sectional study on clinically stable children and adolescents with cystic fibrosis aged from six to 15 years. Participants underwent impulse oscillometry and spirometry evaluations before and 15 minutes after bronchodilator inhalation. The Kolmogorov-Smirnov test was applied to verify the sample distribution, and the Student's t-test and Wilcoxon test were used to compare the data before and after bronchodilator inhalation. Results: The study included 54 individuals with a mean age of 9.7±2.8 years. The analysis showed a statistically significant improvement in impulse oscillometry and spirometry parameters after bronchodilator inhalation. However, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) recommendations (2020 and 2021), this improvement was not sufficient to classify it as a bronchodilator response. Conclusions: The use of bronchodilator medication improved respiratory mechanics and pulmonary function parameters of children and adolescents with cystic fibrosis; however, most patients did not show bronchodilator response according to ATS/ERS recommendations.

show abstract

“…We also used a simplified approach to summing allelic percent function to generate the total expected genotype percent function which warrants confirmation by others. It is possible that the non‐monotonic risk observed in this study may be the result of selection bias in the group of children with more than one CFTR variant because some of them were diagnosed with CF (known to have asthma‐like symptoms 24 ) and thus were removed from the analysis.…”

Section: Discussionmentioning

confidence: 99%

CFTR gene variants, air pollution, and childhood asthma in a California Medicaid population

Thilakaratne

Graham

Moua

et al. 2022

Pediatric Pulmonology

View full text Add to dashboard Cite

Carriers of the cystic fibrosis transmembrane conductance regulator (CFTR) gene ("carriers") have been found to have an increased risk of persistent asthma. However, it is unclear at what level of CFTR function this risk exists and whether it is modified by asthmogens, such as air pollution. We conducted a retrospective cohort study of children born in California between July 2007 and December 2013, linking CFTR genotype data from the California newborn screening program to Medicaid claims records through March 17, 2020 to identify asthma cases, and to air pollution data from CalEnviroScreen 3.0 to identify levels of particulate matter with diameter 2.5 microns or smaller (PM 2.5 ). Log-binomial regression models for asthma risk were fitted, adjusting for race/ethnicity and sex. Compared to population controls, carriers had higher risk of asthma (adjusted risk ratio (aRR) = 1.29, 95% confidence interval (CI): 0.98, 1.69; p < 0.1). Other non-CF-causing variants on the second allele did not appear to further increase risk. Genotypes with the greatest asthma risk were F508del with an intron 10 T7 or (TG)11T5 in trans (aRR=1.52, 95% CI: 1.10, 2.12). This association was higher among children living in areas at or above (aRR = 1.80) versus below (aRR = 1.37) the current national air quality standard for PM 2.5 , though this difference was not statistically significant (p interaction > 0.2). These results suggest carriers with CFTR functional levels between 25% and 45% of wildtype are at increased risk of asthma. Knowledge of CFTR genotype in asthmatics may be important to open new CFTR-related treatment options for these patients.

show abstract

Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome

Cited by 8 publications

References 74 publications

Efficacy of Fluticasone and Salmeterol Dry Powder in Treating Patients with Bronchial Asthma and Its Effect on Inflammatory Factors and Pulmonary Function

Efficacy of Fluticasone and Salmeterol Dry Powder in Treating Patients with Bronchial Asthma and Its Effect on Inflammatory Factors and Pulmonary Function

Bronchodilator response assessment through impulse oscillometry system and spirometry in children and adolescents with cystic fibrosis

CFTR gene variants, air pollution, and childhood asthma in a California Medicaid population

Contact Info

Product

Resources

About